The FDA will finish September with three action dates and one of the year’s most highly-anticipated advisory committee meetings.

Despite concerns regarding neffy’s lack of clinical evidence, the panel of experts voted in favor of the nasal spray’s approval for the emergency treatment of type 1 allergic reactions.

The FDA is kicking off May with three target action dates and three advisory committee meetings, including one for a high-profile investigational gene therapy.